Table 1 Anti-SU IgG fraction neutralizes in vitro FIV infection whereas whole serum enhances infection
Treatment | Factors removed from Serum | Immune factors retained in serum | Effect on FIV replication in vitro |
|---|---|---|---|
Whole serum Sham group | NA | Complement and heat labile factors | NA |
Whole serum CD134 group | NA | Complement and heat labile factors anti-CD134 IgG anti-293S IgG | Enhancement |
Whole serum CD134+SU group | NA | Complement and heat labile factors anti-SU IgG anti-CD134 IgG anti-293S IgG | Enhancement |
Heat-treated serum Sham group | Complement (inactivated) Heat labile factors (inactivated) | NA | NA |
Heat-treated serum CD134 group | Complement (inactivated) Heat labile factors (inactivated) | Anti-CD134 IgG anti-293S IgG | NA |
Heat-treated serum CD134+SU group | Complement (inactivated) Heat labile factors (inactivated) | Anti-SU IgG anti-CD134 IgG anti-293S IgG | Inhibition |
Serum enriched for anti-SU | Complement (inactivated) Heat labile factors (inactivated) anti-CD134 IgG anti-293S IgG | Anti-SU IgG | Inhibition |
Serum enriched for anti-CD134 | Complement (inactivated) Heat labile factors (inactivated) anti-SU IgG anti-293S IgG | Anti-CD134 IgG | NA |
Serum enriched for anti-293S | Complement (inactivated) Heat labile factors (inactivated) anti-SU IgG anti-CD134 IgG | Anti-293S IgG | NA |
